Autopsy report · NCT01556568

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEK162 in Noonan Syndrome Hypertrophic Cardiomyopathy

“Study was withdrawn due to scientific and business considerations.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Array Biopharma, now a wholly owned subsidiary of Pfizer

Sponsor type

Industry

Conditions

Cardiomegaly

Interventions

MEK162

Participants

0

Sites

2

Countries

United Kingdom, United States

Trials that died the same way

• Safety and Efficacy Study for Corneal Collagen Cross-Linking in Eyes With Corneal Ectasia After Refractive Surgery
  “This study was withdrawn for business reasons.” (92% match in meaning)
• Maxi-Analgesic Osteoarthritis (OA) Study
  “The study was withdrawn for administrative reason” (85% match in meaning)
• Gabapentin and Oxcarbazepine for Chronic Neuropathic Pain in Children and Adolescents: A Clinical Effectiveness Study
  “Study was withdrawn for feasibility-related concerns.” (84% match in meaning)
• Dose Ranging Study to Evaluate the Efficacy and Safety of MEDI8852 in Adults Who Are Hospitalized With Type A Influenza.
  “Study is withdrawn due to company decision.” (84% match in meaning)
• Characteristic Analysis and Surgical Exploration for Acetabular Roof Fractures: Multicenter Retrospective Cohort Study
  “Due to limited funding, the study is now being withdrawn.” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.